

Penny E Lovat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5581869/publications.pdf>

Version: 2024-02-01

66
papers

7,172
citations

136950
32
h-index

106344
65
g-index

66
all docs

66
docs citations

66
times ranked

16611
citing authors

#	ARTICLE	IF	CITATIONS
1	Exendin-4 stimulates autophagy in pancreatic Î²-cells via the RAPGEF/EPAC-Ca ²⁺ -PPP3/calcineurin-TFEB axis. <i>Autophagy</i> , 2022, 18, 799-815.	9.1	20
2	Melanoma secretion of transforming growth factor-Î²2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration*. <i>British Journal of Dermatology</i> , 2022, 186, 694-704.	1.5	8
3	Health professional and patient views of a novel prognostic test for melanoma: A theoretically informed qualitative study. <i>PLoS ONE</i> , 2022, 17, e0265048.	2.5	2
4	HPV sensitizes OPSCC cells to cisplatin-induced apoptosis by inhibiting autophagy through E7-mediated degradation of AMBRA1. <i>Autophagy</i> , 2021, 17, 2842-2855.	9.1	25
5	Research Techniques Made Simple: Analysis of Autophagy in the Skin. <i>Journal of Investigative Dermatology</i> , 2021, 141, 5-9.e1.	0.7	7
6	Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model. <i>Health Technology Assessment</i> , 2021, 25, 1-178.	2.8	4
7	Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas. <i>British Journal of Dermatology</i> , 2020, 182, 156-165.	1.5	16
8	TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response. <i>Cancer Cell International</i> , 2019, 19, 53.	4.1	9
9	ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma. <i>Cancers</i> , 2019, 11, 3.	3.7	26
10	Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma. <i>British Journal of Dermatology</i> , 2019, 180, 346-356.	1.5	23
11	Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. <i>British Journal of Cancer</i> , 2018, 118, 495-508.	6.4	47
12	Exposure of Monocytic Cells to Lipopolysaccharide Induces Coordinated Endotoxin Tolerance, Mitochondrial Biogenesis, Mitophagy, and Antioxidant Defenses. <i>Frontiers in Immunology</i> , 2018, 9, 2217.	4.8	45
13	Glucagon-Like Peptide 1 Protects Pancreatic Î²-Cells From Death by Increasing Autophagic Flux and Restoring Lysosomal Function. <i>Diabetes</i> , 2017, 66, 1272-1285.	0.6	102
14	Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing. <i>Journal of Cell Biology</i> , 2017, 216, 1949-1957.	5.2	106
15	Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2016, 6, 236.	2.8	55
16	The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma. <i>British Journal of Dermatology</i> , 2016, 175, 1210-1220.	1.5	32
17	Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization. <i>Autophagy</i> , 2016, 12, 2213-2229.	9.1	118
18	The role of autophagy in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2016, 54, 1-6.	1.5	34

#	ARTICLE	IF	CITATIONS
19	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
20	Exploiting Cannabinoid-Induced Cytotoxic Autophagy to Drive Melanoma Cell Death. Journal of Investigative Dermatology, 2015, 135, 1629-1637.	0.7	126
21	Cellâ€™Type Variation in Stress Responses as a Consequence of Manipulating GRP78 Expression in Neuroectodermal Cells. Journal of Cellular Biochemistry, 2015, 116, 438-449.	2.6	7
22	Fateful music from a talented orchestra with a wicked conductor: Connection between oncogenic BRAF, ER stress, and autophagy in human melanoma. Molecular and Cellular Oncology, 2015, 2, e995016.	0.7	13
23	A Novel Fully Humanized 3D Skin Equivalent to Model Early Melanoma Invasion. Molecular Cancer Therapeutics, 2015, 14, 2665-2673.	4.1	72
24	Established and Emerging Biomarkers in Cutaneous Malignant Melanoma. Healthcare (Switzerland), 2014, 2, 60-73.	2.0	7
25	Prognostic Impact of p62 Expression in Cutaneous Malignant Melanoma. Journal of Investigative Dermatology, 2014, 134, 1476-1478.	0.7	39
26	Induction of endoplasmic reticulum stress as a strategy for melanoma therapy: is there a future?. Melanoma Management, 2014, 1, 127-137.	0.5	13
27	Why is autophagy important for melanoma? Molecular mechanisms and therapeutic implications. Seminars in Cancer Biology, 2013, 23, 337-343.	9.6	46
28	Oncogenic <scp>BRAF</scp> signalling increases <scp>M</scp>clâ€™1 expression in cutaneous metastatic melanoma. Experimental Dermatology, 2013, 22, 767-769.	2.9	35
29	The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide. Oncology Reports, 2011, 27, 293-8.	2.6	5
30	Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition. Clinical Cancer Research, 2011, 17, 2216-2226.	7.0	61
31	FC2 Oncogenic B-RAF signalling confers the resistance of metastatic melanoma to autophagy. Melanoma Research, 2010, 20, e29.	1.2	0
32	Regulation of Endoplasmic Reticulum Stress-induced Cell Death by ATF4 in Neuroectodermal Tumor Cells. Journal of Biological Chemistry, 2010, 285, 6091-6100.	3.4	137
33	Targeting X-Linked Inhibitor of Apoptosis Protein to Increase the Efficacy of Endoplasmic Reticulum Stress-Induced Apoptosis for Melanoma Therapy. Journal of Investigative Dermatology, 2010, 130, 2250-2258.	0.7	33
34	Targeting GRP78 to enhance melanoma cell death. Pigment Cell and Melanoma Research, 2010, 23, 675-682.	3.3	44
35	Combining the Endoplasmic Reticulum Stressâ€™Inducing Agents Bortezomib and Fenretinide as a Novel Therapeutic Strategy for Metastatic Melanoma. Clinical Cancer Research, 2009, 15, 1192-1198.	7.0	59
36	Increasing Melanoma Cell Death Using Inhibitors of Protein Disulfide Isomerases to Abrogate Survival Responses to Endoplasmic Reticulum Stress. Cancer Research, 2008, 68, 5363-5369.	0.9	165

#	ARTICLE	IF	CITATIONS
37	Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 613-622.	4.9	48
38	The Role of MYCN in the Failure of MYCN Amplified Neuroblastoma Cell Lines to G1 Arrest After DNA Damage. Cell Cycle, 2006, 5, 2639-2647.	2.6	44
39	Fenretinide: A p53-independent way to kill cancer cells. Biochemical and Biophysical Research Communications, 2005, 331, 810-815.	2.1	42
40	The role of gangliosides in fenretinide-induced apoptosis of neuroblastoma. Cancer Letters, 2005, 228, 105-110.	7.2	23
41	Gangliosides Link the Acidic Sphingomyelinase-Mediated Induction of Ceramide to 12-Lipoxygenase-Dependent Apoptosis of Neuroblastoma in Response to Fenretinide. Journal of the National Cancer Institute, 2004, 96, 1288-1299.	6.3	84
42	Molecular Mechanisms of Fenretinide-Induced Apoptosis of Neuroblastoma Cells. Annals of the New York Academy of Sciences, 2004, 1028, 81-89.	3.8	40
43	Mechanisms of free-radical induction in relation to fenretinide-induced apoptosis of neuroblastoma. Journal of Cellular Biochemistry, 2003, 89, 698-708.	2.6	33
44	Induction of GADD153 and Bak: novel molecular targets of fenretinide-induced apoptosis of neuroblastoma. Cancer Letters, 2003, 197, 157-163.	7.2	19
45	Growth and DNA Damage-Inducible Transcription Factor 153 Mediates Apoptosis in Response to Fenretinide but Not Synergy between Fenretinide and Chemotherapeutic Drugs in Neuroblastoma. Molecular Pharmacology, 2003, 64, 1370-1378.	2.3	19
46	Glucosylceramide synthase and its functional interaction with RTN-1C regulate chemotherapeutic-induced apoptosis in neuroepithelioma cells. Cancer Research, 2003, 63, 3860-5.	0.9	42
47	Bak: a downstream mediator of fenretinide-induced apoptosis of SH-SY5Y neuroblastoma cells. Cancer Research, 2003, 63, 7310-3.	0.9	27
48	Retinoid signalling and gene expression in neuroblastoma cells: RXR agonist and antagonist effects on CRABP-II and RAR γ expression. Journal of Cellular Biochemistry, 2002, 87, 284-291.	2.6	7
49	GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Research, 2002, 62, 5158-67.	0.9	68
50	Apoptosis in neuroblastomas induced by interferon- γ involves the CD95/CD95L pathway. Medical and Pediatric Oncology, 2001, 36, 115-117.	1.0	5
51	Differential gene regulation by 9-cis and all-trans retinoic acid in neuroblastoma cells. Medical and Pediatric Oncology, 2001, 36, 135-138.	1.0	2
52	Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents. Medical and Pediatric Oncology, 2000, 35, 663-668.	1.0	18
53	Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. International Journal of Cancer, 2000, 88, 977-985.	5.1	55
54	Effector Mechanisms of Fenretinide-Induced Apoptosis in Neuroblastoma. Experimental Cell Research, 2000, 260, 50-60.	2.6	87

#	ARTICLE	IF	CITATIONS
55	Receptor mechanisms mediating differentiation and proliferation effects of retinoids on neuroblastoma cells. <i>Neuroscience Letters</i> , 2000, 279, 113-116.	2.1	8
56	Differential effects of retinoic acid isomers on the expression of nuclear receptor co-regulators in neuroblastoma. <i>FEBS Letters</i> , 1999, 445, 415-419.	2.8	12
57	Retinoid-induced differentiation of neuroblastoma: Comparison between LG69, an RXR-selective analogue and 9-cis retinoic acid. <i>European Journal of Cancer</i> , 1998, 34, 111-117.	2.8	20
58	Retinoids in neuroblastoma therapy: distinct biological properties of 9-cis- and all-trans-retinoic acid. <i>European Journal of Cancer</i> , 1997, 33, 2075-2080.	2.8	38
59	9-cis retinoic acid—a better retinoid for the modulation of differentiation, proliferation and gene expression in human neuroblastoma. <i>Journal of Neuro-Oncology</i> , 1997, 31, 85-91.	2.9	21
60	Gene expression and neuroblastoma cell Differentiation in response to retinoic acid: Differential effects of 9-cis and all-trans retinoic acid. <i>European Journal of Cancer</i> , 1995, 31, 486-494.	2.8	44
61	Concentration-dependent effects of 9-cis retinoic acid on neuroblastoma differentiation and proliferation in vitro. <i>Neuroscience Letters</i> , 1994, 182, 29-32.	2.1	22
62	Retinoic acid receptor expression during the in vitro differentiation of human neuroblastoma. <i>Neuroscience Letters</i> , 1993, 162, 109-113.	2.1	27
63	Serial Study of T Lymphocytes in Childhood Leukemia During Remission. <i>Pediatric Hematology and Oncology</i> , 1993, 10, 129-139.	0.8	13
64	The effects of anesthesia and surgery on lymphocyte populations and function in infants and children. <i>Journal of Pediatric Surgery</i> , 1989, 24, 884-887.	1.6	23
65	Enumeration of lymphocyte subpopulations by immunofluorescent staining of whole blood smears. <i>Journal of Immunological Methods</i> , 1987, 97, 37-40.	1.4	6
66	The Kupffer cell in experimental extrahepatic cholestasis in the rat—a light microscopy, immunohistochemical and electron microscopy study. <i>Journal of Pathology</i> , 1986, 150, 187-194.	4.5	33